Data / Form D filings / NurExone Biologic Inc.
NurExone Biologic Inc.: Form D filings
NurExone Biologic Inc., a biotechnology company in Technion City, Haifa, Israel, filed 11 Form D notices with the SEC between 2023 and 2026. The latest, on August 21, 2026, reports $450,456 sold of a $450,456 offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- MINUS 1 ENTRY, GROUND FLOOR OF BLDG B GUTWIRTH INDUSTRIAL PARK, Technion City, Haifa, Israel, 32000
- Phone
- 972 52-4803034
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Ontario, Canada
- Year incorporated
- 2025
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1995074
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | New notice | $450,456 | $450,456 | 2 | Aug 20, 2026 | sec.gov | |
| Jul 2, 2026 | New notice | $441,779 | $441,779 | 2 | Jun 30, 2026 | sec.gov | |
| Mar 18, 2026 | New notice | $279,910 | $279,910 | 4 | Mar 10, 2026 | sec.gov | |
| Aug 27, 2025 | New notice | $243,231 | $147,846 | $95,385 | 1 | Aug 20, 2025 | sec.gov |
| Apr 22, 2025 | New notice | $3,756,009 | $1,627,604 | $2,128,405 | 1 | Apr 9, 2025 | sec.gov |
| Jan 22, 2025 | New notice | $434,512 | $434,512 | 6 | Jan 21, 2025 | sec.gov | |
| Mar 25, 2024 | New notice | $42,634 | $42,634 | 1 | Mar 22, 2024 | sec.gov | |
| Mar 25, 2024 | New notice | $1,018,224 | $1,018,224 | 4 | Mar 21, 2024 | sec.gov | |
| Mar 25, 2024 | New notice | $430,296 | $430,296 | 5 | Mar 20, 2024 | sec.gov | |
| Jan 9, 2024 | New notice | $2,500,969 | $1,111,542 | $1,389,427 | 3 | Jan 4, 2024 | sec.gov |
| Oct 2, 2023 | New notice | $742,166 | $742,166 | 6 | Aug 25, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Lior Shaltiel | Executive Officer, Director | |
| Eran Ovadya | Executive Officer | |
| Yoram Drucker | Executive Officer, Director | |
| Oded Orgil | Director | |
| David Stolick | Director | |
| Eyal Gabbai | Director |
Every Form D from the week of Aug 17, 2026 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what NurExone Biologic Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.